lonigutamab ugodotin (W0101) / Pierre Fabre, Roche - LARVOL DELTA

A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=316 | Terminated | Sponsor: Pierre Fabre Medicament | Active, not recruiting ➔ Terminated; delay in participants recruitment in cohort A3 and IMP manufacturing issues

Metastases • Trial termination • Oncology • Solid Tumor

A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=316 | Active, not recruiting | Sponsor: Pierre Fabre Medicament | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Oncology • Solid Tumor

"Squiggles Gang. @EmilySnow101010 @rashauddagod @Joel78478188 @GlopesMd @GOLDponyc @Talal90 @Operator_Russo @cartoonftm @HavertyArt" (@Barka96596198)

Identification of a New Antifungal Peptide W1 From a Marine Bacillus amyloliquefaciens Reveals Its Potential in Controlling Fungal Plant Diseases. (PubMed, Front Microbiol) - "Additionally, W1 also had a certain extent of metal ion resistance. These results therefore suggest that the peptide W1 from marine B. amyloliquefaciens W0101 may represent a new antifungal peptide with potential application in the biocontrol of plant diseases."

Journal

Mbarara University Research Training Initiative: Experiences and Accomplishments of the MEPI Junior D43 TW010128 Award in Uganda. (PubMed, Adv Med Educ Pract) - "This was possible due to the positive attitude of the junior faculty (organizational readiness) to change and the supportive environment (mentors and trainers) during implementation of the grant. These two factors provided a favorable institutional climate that guaranteed success of the funding goals."

Journal

"@Honeydew0101 good catalyst" (@JaiSincere)

A pilot study on the impact of combination antiretroviral therapy on spermatogenesis and fertility potential of men living with HIV (EACS 2021) - "Purpose: To determine the effect of combination antiretroviral therapy (cART; tenofovir+Lamivudine+Dolutegravir) on spermatogenesis and fertility potential of HIV positive men. This study shows that 3 months of administration of cART affects the pituitary-gonadal axis depleting testosterone and luteinizing hormones thereby decreasing spermatogenesis and damaging sperm DNA with a plausible reduction on the fertility potential of HIV infected men over time. A larger sample size and a longer duration of the study is recommended. Funding: Fogarty International Center of the National Institutes of Health, Award Number D43TW010134."

Clinical • Human Immunodeficiency Virus • Infectious Disease • CASP7 • CAT • CD4

First-in-Human trial design for W0101, a first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population (ESMO 2018) - P1/2; "Following completion of the dose escalation phase, the expansion phase will enroll up to 4 cohorts of patients prospectively tested for overexpression of IGF-1R to assess preliminary efficacy. A Simon design will be used for futility analysis."

Clinical • P1 data • Head and Neck Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Non Small Cell Lung Cancer

A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2; N=316; Recruiting; Sponsor: Pierre Fabre Medicament; Trial completion date: Sep 2023 ➔ Dec 2024; Trial primary completion date: Jan 2021 ➔ Sep 2022

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A research study of a new investigational medicinal product for the treatment of patients with advanced or metastatic solid tumors (clinicaltrialsregister.eu) - P1/2; N=316; Ongoing; Sponsor: PIERRE FABRE MEDICAMENT

Clinical • New P1/2 trial • Breast Cancer • Hematological Malignancies • Hormone Receptor Breast Cancer • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ER • IGF1

Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies. (PubMed, Front Oncol) - "There are currently three approved antibodies against HNCs (cetuximab, nivolumab, and pembrolizumab), and 48 antibodies under development...In addition, three antibody drug conjugates (ADCs: telisotuzumab-vedotin, indatuximab-ravtansine, and W0101) and two bispecific antibodies (GBR 1372 and ABL001) have been under development...These conjugates combine the high specificity of antibodies with unique spectral properties of GNPs to generate a treatment approach known as photothermal therapy. This approach can provide promising outcomes due to the ability of GNPs to convert light into heat, which can specifically destroy cancer cells and treat HNC in an effective manner."

Journal • Review • Developmental Disorders • Head and Neck Cancer • Infectious Disease • Oncology • Solid Tumor

Facilitators and Barriers to Chronic Disease Self-Management and Mobile Health Interventions for People Living With Diabetes and Hypertension in Cambodia: Qualitative Study. (PubMed, JMIR Mhealth Uhealth) - "These mHealth messages are currently being tested in a cluster randomized controlled trial (#1R21TW010160) to improve diabetes and hypertension control in Cambodia. This study has implications for practice and policies in Cambodia and other LMICs and low-resource US settings that are working to engage PEs and build community-clinical linkages to facilitate chronic disease management."

Journal • Cardiovascular • Diabetes • Heart Failure • Hypertension • Metabolic Disorders

A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2; N=316; Recruiting; Sponsor: Pierre Fabre Medicament; Trial completion date: Sep 2022 ➔ Sep 2023; Trial primary completion date: Jan 2020 ➔ Jan 2021

Clinical • Trial completion date • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Oncology

"Top Influencers of #ENDO2020: @TheEndoSociety @IntMedAbel @MilaNBecker @KirstaSuggs1 @TSW0101 @JoyYWu More 📊 https://t.co/IHtlXykQje" (@healthhashtags)

Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors. (PubMed, Mol Cancer Ther) - "W0101 provides a potential new therapeutic option for patients overexpressing IGF-1R. A first-in-human trial of W0101 is currently ongoing to address clinical safety."

Journal • Preclinical

"Part of Intl./Reg. Panel Discussion between @KerryHallard, @GSA_UK's CEO, @Anil_Bhavnani, @pfizer #India Site Leader & Mark Hentschel, @Telekom_group Head of Processes, moderated by @Francesw0101 from @orangebusiness. #SSONME2019 @ITIDA @ssonetwork" (@loose_gown)

Transcriptomic response of durum wheat to cold stress at reproductive stage. (PubMed, Mol Biol Rep) - "Our results suggest a reprogramming of expression patterns in CBW0101 that affects a number of genes that is closer to the number reported in winter genotypes. These observations could partially explain its moderate tolerance (low proportion of frost-damaged spikes) when exposed to freezing days in the field."

Journal

A Research Study of a New Investigational Medicinal Product for the Treatment of Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2; N=316; Recruiting; Sponsor: Pierre Fabre Medicament; N=36 ➔ 316

Clinical • Enrollment change